Compare MPB & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPB | DNA |
|---|---|---|
| Founded | 1868 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 866.7M | 835.7M |
| IPO Year | 1996 | 2020 |
| Metric | MPB | DNA |
|---|---|---|
| Price | $35.27 | $9.54 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 4 | 3 |
| Target Price | ★ $40.25 | $8.00 |
| AVG Volume (30 Days) | 135.6K | ★ 2.5M |
| Earning Date | 10-21-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.61% | N/A |
| EPS Growth | N/A | ★ 46.49 |
| EPS | ★ 2.07 | N/A |
| Revenue | N/A | ★ $170,155,000.00 |
| Revenue This Year | $28.81 | N/A |
| Revenue Next Year | $9.12 | $7.59 |
| P/E Ratio | $17.03 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $27.98 | $5.37 |
| 52 Week High | $39.15 | $18.22 |
| Indicator | MPB | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 52.00 | 44.51 |
| Support Level | $34.65 | $9.15 |
| Resistance Level | $36.37 | $10.34 |
| Average True Range (ATR) | 0.74 | 1.59 |
| MACD | 0.15 | -0.20 |
| Stochastic Oscillator | 70.29 | 5.65 |
Mid Penn Bancorp Inc is a financial holding company, providing various banking and financial products and services through its subsidiaries. These products and services mainly include consumer banking products, including secure checking and savings accounts, mobile banking, agricultural loans, construction financing, mortgages, home equity loans and lines of credit, credit cards, and more. Additionally, the Group offers trust services, insurance products, wealth management, and private banking services. The Group caters to individuals, partnerships, non-profit organizations, and corporations through its retail banking offices located throughout Pennsylvania, with a minor portion in New Jersey.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.